Finnegan, Henderson, Farabow, Garrett & Dunner has helped the maker of Vagisil products win a district court judgment blocking a competitor from registering Vagisan in the United States.

Vagisan is marketed in Europe by Germany’s Dr. August Wolff GmbH & Co. The company persuaded the U.S. Patent and Trademark Office to register the mark in 2017. The PTO found that the “Vagi-” prefix is strongly suggestive of an intimate feminine care product, and already used by the likes of Vagitone, Vagifresh and Vagicaine. That overcame the commercial strength of Vagisil’s mark.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]